Suspected mediastinal lymph node metastasis in non-small cell lung cancer
Conditions
Interventions
Gold Standard:Histologically confirmed
Index test:Contrast-enhanced CT, 18F-FDG PET/CT, 18F-FAI PET/CT
Sponsors
jiangxi cancer hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age = 18 years, and clinically highly suspected of primary lung cancer (based on imaging or clinical features). 2. Planned to undergo radical lobectomy or pneumonectomy, with consent for concurrent systematic mediastinal lymph node dissection. 3. Able to complete all three multimodal imaging examinations at the designated study imaging center within the specified preoperative time window (e.g., 2–4 weeks). 4. The patient understands the study purpose, procedures, and potential risks, and has voluntarily provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Previous treatment for the currently suspected lung cancer (such as needle biopsy, neoadjuvant chemotherapy/radiotherapy, ablation therapy, etc.). 2. Definitive evidence of distant metastasis (Stage IV) or concurrent other active malignant tumors. 3. Clear contraindications to enhanced CT or PET/CT examinations (e.g., severe allergy to contrast agents, pregnancy, severe renal insufficiency that cannot be corrected). 4. Inability to tolerate the planned surgery as assessed due to cardiopulmonary dysfunction or other severe systemic diseases. 5. Poor compliance or data integrity: inability to cooperate with all study procedures or circumstances that may lead to missing critical data (such as imaging or pathological data).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multimodal Molecular Probe Imaging Features;Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactJiangYeQing
jiangxi cancer hospital
Outcome results
None listed